Skip to content
Financial Insights Unveiled — Master Your Money — Politics — Financial Headlines

Kimberly-Clark to Buy Kenvue for $40B; Supreme Court to Weigh Trump's Tariff Powers

Kimberly-Clark's big pharma move. Supreme Court to rule on Trump's tariff authority.

,   and  Administrator
1 min read
As we can see in the image there is a clear sky and at the bottom there are buildings and in...
As we can see in the image there is a clear sky and at the bottom there are buildings and in between there is a bridge on which a metro train is passing and in between there are electric poles which are connected to electric wires and below it there is a ploughing vehicle and beside it there are plants and trees and between them there is a black tent and beside it there is a fencing.

Kimberly-Clark to Buy Kenvue for $40B; Supreme Court to Weigh Trump's Tariff Powers

Kimberly-Clark, a multinational personal care corporation, has agreed to purchase Kenvue, the company behind popular brands like Tylenol, for over $40 billion. Meanwhile, the Supreme Court is set to deliberate on President Trump's tariff-imposing powers this week, with his legal team presenting arguments.

The acquisition, valued at more than $40 billion, will see Kimberly-Clark expand its portfolio to include over-the-counter medications. The deal is expected to close in the second half of 2023, subject to regulatory approvals.

In legal news, the Supreme Court will consider a case challenging President Trump's authority to impose tariffs under the International Emergency Economic Powers Act. The case, Trump v. 45 John Doe, will be argued by Trump's legal team this week.

Kimberly-Clark's purchase of Kenvue signals a significant move into the pharmaceutical sector. Meanwhile, the Supreme Court's decision on President Trump's tariff powers is anticipated to have substantial implications for future administrations.

Read also:

Related

Latest